Newsfeeds - Spark Newswire

4 minute read

46 Stocks Moving In Friday’s Mid-Day Session

By Lisa Levin

Today, 5:22 PM

Gainers Kanzhun Limited (NASDAQ: BZ) shares surged 77.4% to $33.70 after the company priced its IPO at $19 per share.

AEHL

1 minute read

Vertex, Crispr Unveil More Encouraging Data From Sickle Cell, Thalassemia Gene Therapy Trials

By Vandana Singh

Today, 5:22 PM

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Crispr Therapeutics AG (NASDAQ:CRSP) have announced new data from Phase 1/2 clinical trials evaluating CTX001 in beta-thalassemia and…

CRSP

1 minute read

Morgan Stanley Maintains Equal-Weight on Vertex Pharmaceuticals, Lowers Price Target to $205

By Benzinga Newsdesk

Today, 5:22 PM

Morgan Stanley analyst Matthew Harrison maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Equal-Weight and lowers the price target from $254 to $205.

VRTX

1 minute read

Citigroup Maintains Buy on Vertex Pharmaceuticals, Lowers Price Target to $285

By Benzinga Newsdesk

Today, 5:22 PM

Citigroup analyst Mohit Bansal maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and lowers the price target from $325 to $285.

VRTX

1 minute read

Baird Maintains Outperform on Vertex Pharmaceuticals, Lowers Price Target to $240

By Benzinga Newsdesk

Today, 5:22 PM

Baird analyst Brian Skorney maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and lowers the price target from $252 to $240.

VRTX

1 minute read

Goldman Sachs Maintains Buy on Vertex Pharmaceuticals, Lowers Price Target to $307

By Benzinga Newsdesk

Today, 5:22 PM

Goldman Sachs maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and lowers the price target from $358 to $307.

VRTX

1 minute read

Cantor Fitzgerald Maintains Overweight on Vertex Pharmaceuticals, Lowers Price Target to $281

By Benzinga Newsdesk

Today, 5:22 PM

Cantor Fitzgerald analyst Alethia Young maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and lowers the price target from $285 to $281.

VRTX